Top Markets
#1 Helium Helium +47.34%
#2 TENDIES TENDIES +43.82%
#3 Pons Pons +38.81%
#4 UnifAI Network UnifAI Network +18.28%
#5 Seeker Seeker +16.90%
#6 Songbird Songbird +15.77%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +10.42%
#8 DAPPOS DAPPOS +10.15%
#9 OSK OSK +10.10%
#10 Bounce Bounce +9.81%
Coin of the day
Helium Helium
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Classement en actions #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Prix de l'action
$9.50
Dernière synchronisation: 2025-01-08
Capitalisation boursière
$819.52M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Poseida Therapeutics, Inc. (PSTX)

Catégorie

Healthcare
Nombre d'actions en circulation pour Poseida Therapeutics, Inc. (PSTX)
Nombre d'actions en circulation au September 2024: 97.16M
Selon les derniers rapports financiers et le cours de l'action de Poseida Therapeutics, Inc., le nombre actuel d'actions en circulation est de 97.16M. À la fin de December 2022, l'entreprise avait 71.91M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Poseida Therapeutics, Inc. (PSTX) de 2016 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
2026 (TTM) 97.16M 7.73%
2023 90.19M 25.41%
2022 71.91M 15.66%
2021 62.18M 6.47%
2020 58.40M 46.98%
2019 39.73M 10.59%
2018 35.93M -9.57%
2017 39.73M -33.01%
2016 59.32M 0.00%
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 161.32%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -36.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 392.91%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 307.57%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH